Single-Cell Proteomics Workflow for Cancer Research
Call for Papers – Special Issue

*Cancer Biomarkers* is planning a special issue entitled “Single-Cell Proteomics Workflow for Cancer Research” (Guest Editor: Tao Liu, PhD), due for publication in 2023, to showcase perspectives or research on state-of-the-art single-cell proteomics methods, platforms, computational tools, and relevant applications in cancer. We hope to inspire the omics community to learn, discuss, and apply these strategies and tools in their cancer research.

**About the Topic:** The ability to effectively measure the variability of individual cells is crucial to understanding oncogenesis, a process that is driven primarily by cell-intrinsic properties. Advances in this area will help address critical issues that are closely related to cancer progression, resistance to therapy, or recurrence, e.g., intratumor heterogeneity and tumor-stroma interaction. The success in developing effective biomarkers for more accurate detection of early-stage cancers and precancerous lesions or more effective treatment will be significantly influenced by our ability to make such measurements. The advent of single-cell sequencing has propelled tremendous progress in deep, large-scale profiling of genetic, epigenetic, or transcriptional variations in individual cells. As the next/parallel step, it is critical to measure proteins, the effector molecules of the cellular processes, to understand the underlying mechanisms for improved early detection and therapeutic intervention. Indeed, single-cell proteomics has made significant progress in the last several years, starting to overcome tremendous technical challenges and demonstrate groundbreaking applications in basic and biomedical research.

Full manuscripts will be considered up until January 15, 2023 and submitted papers should not be under consideration for publication elsewhere. Authors are requested to submit their manuscript electronically via the journal’s editorial management system, selecting the section “Single-Cell Proteomics Workflow for Cancer Research” on submission. For information on formatting your manuscript, please see the author instructions here.

**About the Guest Editor:** Tao Liu, PhD, is a Senior Staff Scientist at the Pacific Northwest National Laboratory, USA, and the Principal Investigator of several omics cancer research programs, such as the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC) and the NCI Early Detection Research Network (EDRN). His research focuses on the development and application of advanced mass spectrometry technologies for integrated post-translational modification, single-cell, and multi-omic characterization of cancers, leading to improved understanding of aberrant regulatory and signaling networks underlying cancers, as well as cancer biomarker discovery and verification.

**About the Journal:** *Cancer Biomarkers* is a peer-reviewed print and online journal with an Impact Factor of 3.828, according to Journal Citation Reports (Clarivate, 2022). Led by Editor-in-Chief Sudhir Srivastava, PhD, MPH, the journal is supported by an international Editorial Board consisting of a distinguished team of cancer researchers from major institutes around the world. More details: [iospress.com/cancer-biomarkers](https://iospress.com/cancer-biomarkers).

**Submission deadline:**
January 15, 2023

If you have queries about the submission procedure, please contact the Editorial Office:

**Gabriela Ricci**
g.ricci@iospress.nl